Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
What strategies do you implement to control the nausea from Enhertu?
Related Questions
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
What is your recommended treatment sequencing strategy in patients with HER2+ breast cancer and leptomeningeal carcinomatosis?
What are your top takeaways in Breast Cancer from ESMO 2024?
Do you continue ovarian suppression for metastatic hormone-positive breast cancer patients who are premenopausal, regardless of line of therapy?
How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
What are your top takeaways in Medical Oncology from SABCS 2024?
